Jun 11 2010
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced the company's new focused RNAi therapeutic strategy at the Jefferies 2010 Global Life Sciences Conference.
RXi's therapeutic platform has the potential to be broadly applicable to multiple therapeutic areas and indications. The company's core focus leverages RXi's unique technologies and competencies to advance potential candidates in select therapeutic areas with attractive market potential. RXi will also explore additional indications of strategic interest to the company which will be advanced internally and with partners through preclinical studies. As RXi executes on its core focus and strategic interest areas, additional areas may be pursued opportunistically.
Core Focus: RXi will focus its internal therapeutic development efforts in two main areas:
Strategic Interest: RXi will explore additional indications through preclinical development that are of strategic interest to the company and may provide partnership opportunities.
Opportunistic Pursuit: RXi will continue to evaluate multiple opportunities and is prepared to engage in more active therapeutic development in cases where a program is funded by a partner or where RXi attains promising initial results. These opportunities could be in a variety of areas, such as Hepatic (HCV), Respiratory (Asthma, COPD), Oncology, and others.
SOURCE RXi Pharmaceuticals Corporation
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients